By Kris B. Mamula, Pittsburgh Business Times
Uptown Pittsburgh-based Cernostics Inc. will receive $100,000 in funding to advance development of its lead product, which will help diagnose patients at risk for esophageal cancer.
The Ben Franklin Technology Partners of Northeastern Pennsylvania provided the funds. Cernostics is collaborating with health care organizations worldwide to bring its TissueCypher product to market, including Geisinger Health System, University of Pittsburgh and the University of Pennsylvania.